New England Journal of Medicine November 09, 2026

ANGPTL4 Inhibition in Adults with Elevated Triglyceride Levels

Michelle L O'Donoghue, Rebecca A Juliano, B Alexander Yi, et al.

Bottom Line

In a phase 2b trial of adults with elevated triglycerides and remnant cholesterol, the monoclonal antibody MAR001 directed against ANGPTL4 significantly reduced fasting triglyceride levels at 12 weeks with an acceptable safety profile.

Key Findings

1. At week 12, placebo-adjusted least-squares mean percent changes in fasting triglyceride levels were -39.1, -40.5, and -45.3 percentage points for the 300-mg, 450-mg, and 900-mg MAR001 doses, respectively (P<0.001 for all comparisons).
2. Adverse events were reported in 69% (123 of 177) of participants in the pooled MAR001 group, compared to 78% (45 of 58) of those in the placebo group, showing no substantial increase in adverse events with the active drug.
3. The median baseline fasting triglyceride level in the trial population (mean age 60.4 years, 39% women) was 249.5 mg per deciliter.

Study Design

Design
RCT
Double-Blind
Sample
236
Patients
Duration
24 wk
Median
Setting
Multicenter
Population Adults with nonfasting triglycerides ≥175 mg/dL and remnant cholesterol ≥35 mg/dL on initial screening, confirmed by fasting triglycerides ≥150 mg/dL and remnant cholesterol ≥30 mg/dL.
Intervention MAR001 (a monoclonal antibody against ANGPTL4) administered subcutaneously at doses of 300, 450, or 900 mg every 4 weeks.
Comparator Matching placebo administered subcutaneously every 4 weeks.
Outcome Percent change from baseline in the fasting triglyceride level at week 12 (reported as placebo-adjusted change).

Study Limitations

• The trial was designed as a phase 2b biomarker study and was not powered or sized to assess the impact of MAR001 on hard clinical endpoints, such as acute pancreatitis or major adverse cardiovascular events.
• The primary efficacy evaluation was limited to a relatively short follow-up of 12 weeks, meaning the long-term durability and safety of prolonged ANGPTL4 inhibition remains to be established.
• The study cohort was relatively small (N=236), which limits the ability to detect rare or idiosyncratic adverse events.

Clinical Significance

This trial provides critical proof-of-concept that targeting ANGPTL4 with the monoclonal antibody MAR001 securely and effectively lowers triglycerides and remnant cholesterol in humans. Given previous preclinical challenges associated with ANGPTL4 inhibition, demonstrating clinical safety alongside robust efficacy establishes a vital foundation for evaluating this pathway as a therapeutic strategy for mitigating residual cardiometabolic risk.

Historical Context

Triglyceride-rich lipoproteins have increasingly been recognized as independent drivers of residual atherosclerotic cardiovascular disease risk, spurring the development of novel targeted therapies. While targeting ANGPTL3 (e.g., evinacumab) successfully transitioned to clinical use, therapeutic development targeting ANGPTL4—a related endogenous inhibitor of lipoprotein lipase—was previously hindered by preclinical safety concerns, such as severe mesenteric lymphadenitis seen in knockout models. The TYDAL-TIMI 78 trial (reporting on MAR001) is a landmark milestone, showing that pharmacological ANGPTL4 inhibition in humans can evade these historical preclinical toxicities while powerfully improving the lipid profile.

Guided Discussion

High-yield insights from every perspective

Med Student
Medical Student

How does the pharmacological inhibition of ANGPTL4 biochemically result in the reduction of fasting triglyceride levels, and what specific endogenous enzyme is being directly disinhibited?

Key Response

ANGPTL4 is a physiologic inhibitor of lipoprotein lipase (LPL). By using a monoclonal antibody like MAR001 to block ANGPTL4, LPL is disinhibited, which increases the hydrolysis of triglycerides within circulating very-low-density lipoproteins (VLDL) and chylomicrons into free fatty acids, thereby facilitating their rapid clearance from the bloodstream.

Resident
Resident

For a patient presenting with severe hypertriglyceridemia, how would a future ANGPTL4 inhibitor like MAR001 potentially alter our current pharmacological algorithm, which currently relies on statins, fibrates, and icosapent ethyl?

Key Response

Statins are first-line for ASCVD risk reduction, while fibrates and omega-3 fatty acids are traditionally used to lower triglycerides to prevent acute pancreatitis. MAR001 could serve as a highly potent alternative for refractory severe hypertriglyceridemia to rapidly prevent pancreatitis or, depending on future trial data, be used to specifically lower remnant cholesterol to reduce residual cardiovascular risk where fibrates have largely failed.

Fellow
Fellow

Evinacumab, an ANGPTL3 inhibitor, is already approved for severe hypercholesterolemia. From a physiological and subspecialty perspective, how does targeting ANGPTL4 differ from targeting ANGPTL3 in the management of atherogenic dyslipidemia?

Key Response

While ANGPTL3 acts primarily in the liver affecting both LDL and triglycerides via endothelial lipase and LPL, ANGPTL4 is highly expressed in adipose tissue and skeletal muscle, tightly regulating LPL during fasting and feeding states. Understanding these tissue-specific expression patterns is crucial for predicting specific lipid fraction alterations, such as remnant cholesterol clearance, and tissue-specific side effects.

Attending
Attending

The trial highlights significant reductions in remnant cholesterol alongside fasting triglycerides. Given the ongoing debate surrounding residual cardiovascular risk despite aggressive LDL-C lowering, how might MAR001 change our long-term preventative cardiology practices compared to older triglyceride-lowering agents?

Key Response

Traditional triglyceride-lowering drugs like fibrates have largely failed to show consistent cardiovascular outcome benefits in statin-treated patients (e.g., the PROMINENT trial). However, Mendelian randomization shows remnant cholesterol is a direct causal factor for ASCVD. If MAR001 effectively clears these atherogenic remnants rather than just lowering numerical triglycerides, it may finally offer a targeted tool to reduce residual ASCVD risk.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD
PhD

Previous preclinical studies of ANGPTL4 knockout mice revealed lethal mesenteric lymphadenopathy and lipogranulomatous lesions on high-fat diets. How should a clinical trial for an ANGPTL4 inhibitor be methodologically designed to monitor for these specific, diet-dependent toxicities?

Key Response

The historic preclinical toxicity of ANGPTL4 inhibition stalled its early development. A rigorous trial must incorporate advanced abdominal imaging and specialized biomarker tracking for macrophage lipid accumulation. Researchers must critically evaluate whether a 12-week Phase 2b trial is of sufficient duration to capture these insidious pathophysiological changes that were highly diet-dependent in animal models.

Journal Editor
Journal Editor

As a peer reviewer evaluating this 12-week Phase 2b trial, what critical limitations regarding the study duration and safety endpoints would you flag before accepting the authors' conclusion of an 'acceptable safety profile'?

Key Response

A 12-week trial is fundamentally inadequate to establish long-term safety for a novel biological target with known preclinical red flags like mesenteric lipidosis. A tough reviewer would scrutinize the statistical power for rare adverse events and demand transparency on whether fasting surrogate endpoints adequately capture the dynamic postprandial lipid shifts regulated by ANGPTL4.

Guideline Committee
Guideline Committee

Current ACC/AHA cholesterol guidelines emphasize statins and icosapent ethyl for ASCVD risk reduction in hypertriglyceridemia, largely reserving other agents for pancreatitis prevention. What specific trial endpoints must MAR001 achieve to secure a Class I recommendation for ASCVD risk reduction?

Key Response

Current guidelines (e.g., the 2018 AHA/ACC Multi-society Guideline on Blood Cholesterol) only recognize icosapent ethyl based on the REDUCE-IT trial for mitigating residual cardiovascular risk in patients with elevated triglycerides. To update these guidelines for MAR001, a Phase 3 cardiovascular outcomes trial (CVOT) must demonstrate a statistically significant reduction in hard MACE (Major Adverse Cardiovascular Events) on top of maximally tolerated statin therapy.

Clinical Landscape

Noteworthy Related Trials

2018

REDUCE-IT Trial

n = 8,179 · NEJM

Tested

Icosapent ethyl 4g daily

Population

Patients with elevated triglycerides and established CVD or diabetes

Comparator

Placebo (mineral oil)

Endpoint

Composite of CV death, nonfatal MI, nonfatal stroke, coronary revascularization, or unstable angina

Key result: Icosapent ethyl significantly reduced the risk of the primary composite cardiovascular endpoint by 25 percent compared to placebo.
2022

TRANSLATE-TIMI 70 Trial

n = 286 · Circulation

Tested

Vupanorsen (ANGPTL3 antisense oligonucleotide)

Population

Adults with non-HDL-C >= 100 mg/dL and TG 150-500 mg/dL on statin therapy

Comparator

Placebo

Endpoint

Percent change in non-HDL-C at 24 weeks

Key result: Vupanorsen significantly reduced non-HDL-C and triglycerides but led to dose-dependent increases in hepatic fat fraction and liver enzymes.
2022

PROMINENT Trial

n = 10,497 · NEJM

Tested

Pemafibrate 0.2 mg twice daily

Population

T2DM patients with mild-to-moderate hypertriglyceridemia and low HDL-C

Comparator

Placebo

Endpoint

Composite of nonfatal MI, ischemic stroke, coronary revascularization, or CV death

Key result: Pemafibrate effectively lowered triglyceride levels by 26.2 percent but failed to reduce the incidence of cardiovascular events compared to placebo.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis
↑